T
Timo Otonkoski
Researcher at University of Helsinki
Publications - 79
Citations - 7304
Timo Otonkoski is an academic researcher from University of Helsinki. The author has contributed to research in topics: Induced pluripotent stem cell & Cellular differentiation. The author has an hindex of 36, co-authored 79 publications receiving 6431 citations. Previous affiliations of Timo Otonkoski include Helsinki University Central Hospital & Turku University Hospital.
Papers
More filters
Journal ArticleDOI
Characterization of human embryonic stem cell lines by the International Stem Cell Initiative
Oluseun Adewumi,Behrouz Aflatoonian,Lars Ährlund-Richter,Michal Amit,Peter W. Andrews,Gemma Beighton,Paul Bello,Nissim Benvenisty,Lorraine S. Berry,Simon Bevan,Barak Blum,Justin Brooking,Kevin G. Chen,Andre Bh Choo,Gary A. Churchill,Marie Corbel,Ivan Damjanov,John S Draper,Petr Dvorak,Petr Dvorak,Katarina Emanuelsson,Roland A. Fleck,Angela Ford,Karin Astrid Maria Gertow,Karin Astrid Maria Gertow,Marina Gertsenstein,Paul J. Gokhale,Rebecca S. Hamilton,Alex Hampl,Alex Hampl,Lyn Healy,Outi Hovatta,Johan Hyllner,Marta P. Imreh,Marta P. Imreh,Joseph Itskovitz-Eldor,Jamie P. Jackson,Jackie Johnson,Mark Jones,Kehkooi Kee,Benjamin L. King,Barbara B. Knowles,Majlinda Lako,Franck Lebrin,Barbara S. Mallon,Daisy Manning,Yoav Mayshar,Ronald D.G. McKay,Anna E. Michalska,Milla Mikkola,Masha Mileikovsky,Stephen L. Minger,Harry Moore,Christine L. Mummery,Andras Nagy,Norio Nakatsuji,Carmel M. O’Brien,Steve Oh,Cia Olsson,Timo Otonkoski,Kye-Yoon Park,Robert Passier,Hema Patel,Minal Patel,Roger A. Pedersen,Martin F. Pera,Marian S Piekarczyk,Renee A. Reijo Pera,Benjamin Reubinoff,Allan J. Robins,Janet Rossant,Peter J. Rugg-Gunn,Peter J. Rugg-Gunn,Thomas C Schulz,Henrik Semb,Eric S Sherrer,Henrike Siemen,Glyn Stacey,Miodrag Stojkovic,Hirofumi Suemori,Jin P. Szatkiewicz,Tikva Turetsky,Timo Tuuri,Steineke van den Brink,Kristina Vintersten,Sanna Vuoristo,Dorien Ward,Thomas A Weaver,Lesley Young,Weidong Zhang +89 more
TL;DR: The International Stem Cell Initiative characterized 59 human embryonic stem cell lines from 17 laboratories worldwide and found that despite diverse genotypes and different techniques used for derivation and maintenance, all lines exhibited similar expression patterns for several markers ofhuman embryonic stem cells.
Journal ArticleDOI
Copy number variation and selection during reprogramming to pluripotency
Samer M.I. Hussein,Nizar N. Batada,Sanna Vuoristo,Reagan W. Ching,Reija Autio,Reija Autio,Elisa Närvä,Siemon Ng,Michel Sourour,Riikka H. Hämäläinen,Cia Olsson,Karolina Lundin,Milla Mikkola,Ras Trokovic,Michael Peitz,Oliver Brüstle,David P. Bazett-Jones,Kari Alitalo,Riitta Lahesmaa,Andras Nagy,Timo Otonkoski +20 more
TL;DR: It is shown that significantly more CNVs are present in early-passage human iPS cells than intermediate passage human i PS cells, fibroblast cell origins and with human embryonic stem (ES) cells.
Journal ArticleDOI
Screening ethnically diverse human embryonic stem cells identifies a chromosome 20 minimal amplicon conferring growth advantage
Katherine Amps,Peter W. Andrews,George Anyfantis,Lyle Armstrong,Stuart Avery,Hossein Baharvand,Julie C. Baker,Duncan Baker,Maria D. Barbadillo Muñoz,Stephen J. Beil,Nissim Benvenisty,Dalit Ben-Yosef,Juan Carlos Biancotti,Alexis Bosman,Romulo M. Brena,Daniel R. Brison,Gunilla Caisander,Marãa V. Camarasa,Jieming Chen,Eric Chiao,Young Min Choi,Andre Choo,D.M. Collins,Alan Colman,Jeremy M. Crook,George Q. Daley,Anne Dalton,Paul A. De Sousa,Chris Denning,J.M. Downie,Petr Dvorak,Karen Dyer Montgomery,Anis Feki,Angela Ford,Victoria Fox,Ana Maria Fraga,Tzvia Frumkin,Lin Ge,Paul J. Gokhale,Tamar Golan-Lev,Hamid Gourabi,Michal Gropp,Lu GuangXiu,Aleš Hampl,Katie Harron,Lyn Healy,Wishva Herath,Frida Holm,Outi Hovatta,Johan Hyllner,Maneesha S. Inamdar,Astrid K. Irwanto,Tetsuya Ishii,Marisa Jaconi,Ying Jin,Susan J. Kimber,Sergey Kiselev,Barbara B. Knowles,Oded Kopper,Valeri Kukharenko,Anver Kuliev,Maria A. Lagarkova,Peter W. Laird,Majlinda Lako,Andrew L. Laslett,Neta Lavon,Dong Ryul Lee,Jeoung Eun Lee,Chunliang Li,Linda S. Lim,Tenneille Ludwig,Yu Ma,Edna Maltby,Ileana Mateizel,Yoav Mayshar,Maria Mileikovsky,Stephen L. Minger,Takamichi Miyazaki,Shin Yong Moon,Harry Moore,Christine L. Mummery,Andras Nagy,Norio Nakatsuji,Kavita Narwani,Steve Oh,Sun Kyung Oh,Cia Olson,Timo Otonkoski,Fei Pan,In-Hyun Park,Steve Pells,Martin F. Pera,Lygia da Veiga Pereira,Ouyang Qi,Grace Selva Raj,Benjamin Reubinoff,Alan Robins,Paul Robson,Janet Rossant,Ghasem Hosseini Salekdeh,Thomas C. Schulz,Karen Sermon,Jameelah Sheik Mohamed,Hui Shen,Eric S Sherrer,Kuldip S. Sidhu,Shirani Sivarajah,Heli Skottman,Claudia Spits,Glyn Stacey,Raimund Strehl,Nick Strelchenko,Hirofumi Suemori,Bowen Sun,Riitta Suuronen,Kazutoshi Takahashi,Timo Tuuri,Parvathy Venu,Yuri Verlinsky,Dorien Ward-van Oostwaard,Daniel J. Weisenberger,Yue Wu,Shinya Yamanaka,Lorraine E. Young,Qi Zhou +124 more
TL;DR: Of these genes, BCL2L1 is a strong candidate for driving culture adaptation of ES cells, and single-nucleotide polymorphism analysis revealed that they included representatives of most major ethnic groups.
Journal ArticleDOI
Activating germline mutations in STAT3 cause early-onset multi-organ autoimmune disease
Sarah E. Flanagan,Emma Haapaniemi,Mark Russell,Richard Caswell,Hana Lango Allen,Elisa De Franco,Timothy J. McDonald,Hanna Rajala,Hanna Rajala,Anita Ramelius,John Barton,Kaarina Heiskanen,Kaarina Heiskanen,Tarja Heiskanen-Kosma,Merja Kajosaari,Nuala Murphy,Tatjana Milenkovic,Mikko Seppänen,Åke Lernmark,Satu Mustjoki,Satu Mustjoki,Timo Otonkoski,Timo Otonkoski,Juha Kere,Noel G. Morgan,Sian Ellard,Andrew T. Hattersley +26 more
TL;DR: A new monogenic cause of autoimmunity resulting from de novo germline activating STAT3 mutations in five individuals with a spectrum of early-onset autoimmune disease, including type 1 diabetes is reported.
Journal ArticleDOI
GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus
Johnny Ludvigsson,David Krisky,Rosaura Casas,Tadej Battelino,Luis Castaño,James Greening,Olga Kordonouri,Timo Otonkoski,Paolo Pozzilli,Jean-Jacques Robert,H. J. Veeze,Jerry P. Palmer,Diamyd Medical +12 more
TL;DR: Treatment with GAD-alum did not significantly reduce the loss of stimulated C peptide or improve clinical outcomes over a 15-month period, and the primary outcome did not differ significantly between the combined active-drug groups and the placebo group.